Disclosures for "Patient Perspectives on Barriers to Diagnosis and Treatment of Tardive Dyskinesia from a Cross-sectional Survey"
-
Ms. Solis has received personal compensation for serving as an employee of Teva Pharmaceuticals.
-
Nayla Chaijale has received personal compensation for serving as an employee of Teva Pharmaceuticals.
-
Ms. Gonzalez has received personal compensation for serving as an employee of Teva Pharmaceuticals. Ms. Gonzalez has received personal compensation for serving as an employee of Teva Pharmaceuticals. Ms. Gonzalez has stock in Teva Pharmaceuticals.
-
Dr. Zhang has received personal compensation for serving as an employee of Teva. Dr. Zhang has stock in Teva.
-
Mr. Ahn has nothing to disclose.
-
Ms. Luo has received personal compensation for serving as an employee of TechData Service, Inc..
-
Ms. Overbaugh has received personal compensation for serving as an employee of Research Catalyst, LLC.
-
Dr. Suett has received personal compensation for serving as an employee of Teva. Dr. Suett has stock in Teva.
-
Dr. Tian has received personal compensation for serving as an employee of Teva Pharmaceuticals. Dr. Tian has stock in Teva Pharmaceuticals.
-
Dr. Ramirez Campos has received personal compensation for serving as an employee of teva.
-
The institution of Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Teva Pharmaceuticals. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda Therapeutics. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevel Therapeutics. Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevance. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ferrer. Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Research Catalyst, LLC. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for CenExel RMCR. Dr. Kumar has stock in Research Catalyst, LLC. Dr. Kumar has stock in CenExel. Dr. Kumar has stock in Neurofold Therapeutics. The institution of Dr. Kumar has received research support from Supernus. The institution of Dr. Kumar has received research support from Sage Therapeutics. The institution of Dr. Kumar has received research support from Prilenia Therapeutics. The institution of Dr. Kumar has received research support from Roche. The institution of Dr. Kumar has received research support from Triplet Therapeutics. The institution of Dr. Kumar has received research support from CHDI Foundation. The institution of Dr. Kumar has received research support from Neurocrine Biosciences. The institution of Dr. Kumar has received research support from Biovie. The institution of Dr. Kumar has received research support from Neuroderm. The institution of Dr. Kumar has received research support from Sanofi. The institution of Dr. Kumar has received research support from Addex Pharma. The institution of Dr. Kumar has received research support from Integrative Research Laboratories. The institution of Dr. Kumar has received research support from Takeda Pharmaceuticals. The institution of Dr. Kumar has received research support from Neuraly. The institution of Dr. Kumar has received research support from Abbvie. The institution of Dr. Kumar has received research support from Cerevel Therapeutics. The institution of Dr. Kumar has received research support from Transposon Therapeutics. The institution of Dr. Kumar has received research support from Lundbeck. The institution of Dr. Kumar has received research support from Biohaven. The institution of Dr. Kumar has received research support from Revance Therapeutics. The institution of Dr. Kumar has received research support from Impax Laboratories. The institution of Dr. Kumar has received research support from CND Life Sciences. The institution of Dr. Kumar has received research support from Neuron23. The institution of Dr. Kumar has received research support from Annexon Biosciences. The institution of Dr. Kumar has received research support from Annovis. The institution of Dr. Kumar has received research support from PTC Therapeutics. The institution of Dr. Kumar has received research support from Uniqure. The institution of Dr. Kumar has received research support from Alexza. The institution of Dr. Kumar has received research support from SparkNeuro. The institution of Dr. Kumar has received research support from Praxis. The institution of Dr. Kumar has received research support from Scion Neurostim. The institution of Dr. Kumar has received research support from Cognition Therapeutics. The institution of Dr. Kumar has received research support from Eli Lilly. The institution of Dr. Kumar has received research support from Aribio. The institution of Dr. Kumar has received research support from Biogen. The institution of Dr. Kumar has received research support from Bial R and D investments. The institution of Dr. Kumar has received research support from Ono Pharmaceutical Company. The institution of Dr. Kumar has received research support from UCB Biopharma. The institution of Dr. Kumar has received research support from Vigil Therapeutics. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Medical Director with CenExel RMCR. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as a Managing Member with Research Catalyst, LLC. Dr. Kumar has a non-compensated relationship as a Board Member with Movement Disorders Foundation that is relevant to AAN interests or activities.